MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 6, 2008, Pages 646-651

  Durelli, L ^a,e   Barbero, P ^a   Bergui, M ^a   Versino, E ^a   Bassano, M A ^b   Verdun, E ^a   Rivoiro, C ^a   Ferrera, C ^a   Picco, E ^a   Ripellino, P ^a   Giuliani, G ^c   Montanari, E ^d   Clerico, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Dimensione Ricerca   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d Ospedale Civile   (Italy)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; INTERFERON ANTIBODY; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; ANTIBODY; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B; RECOMBINANT PROTEIN;

ADULT; ANTIBODY TITER; ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; BRAIN; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; SERODIAGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES; BRAIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROLOGIC EXAMINATION; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 44449105085     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2007.130229     Document Type: Article

References (29)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 1993;43:655-61.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1 a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
4. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-7.
5. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1 b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60.
6. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1 a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506.
7. Killestein J, Hintzen RQ, Uitdehaag BM, et al. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J Neuroimmunol 2002;133:217-24.
8. Petereit HF, Nolden S, Schoppe S, et al. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002;8:492-4.
9. Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036-43.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444- 52.
11. Rio J, Nos C, Tintore M. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-52.
12. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16.
13. Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36(Suppl):S86-90.
14. Kappos L, Moeri D, Radue EW. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-9.
15. Weiner HL, Guttmann CR, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol 2000;104:164-73.
16. Calabresi PA, Stone LA, Bash C. Interferon beta results in immediate reducion of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997;48:1446-8.
17. Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 1997;49:647-50.
18. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-84.
19. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-27.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
21. Pungor E Jr, Files JG, Gabe JD. A novel bioassay for the determination of neutralizing antibodies to IFN-beta-1b. J Interferon Cytokine Res 1998;18:1025-30.
22. Paty DW, Li DK. Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7.
23. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55.
24. Sorensen PS, Koch-Henriksen N, Ravnborg M, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006;12:253-64.
25. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-9.
26. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7.
27. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127:1463-78.
28. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-93.
29. Barkhof F, van Walderveen M. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos Trans R Soc Lond B Biol Sci 1999;354:1675-86.